Cantor Fitzgerald Reiterates Overweight Rating for COMPASS Pathways (NASDAQ:CMPS)

COMPASS Pathways (NASDAQ:CMPS)‘s stock had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald in a report released on Thursday, Benzinga reports.

CMPS has been the subject of a number of other reports. Morgan Stanley initiated coverage on shares of COMPASS Pathways in a report on Monday, April 1st. They issued an “overweight” rating and a $30.00 target price for the company. HC Wainwright restated a “buy” rating and issued a $120.00 target price on shares of COMPASS Pathways in a report on Friday, March 1st. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has an average rating of “Buy” and an average price target of $47.40.

COMPASS Pathways Stock Performance

Shares of NASDAQ CMPS opened at $8.38 on Thursday. The company has a market cap of $519.06 million, a PE ratio of -3.51 and a beta of 2.48. COMPASS Pathways has a 12 month low of $5.01 and a 12 month high of $12.75. The company has a debt-to-equity ratio of 0.14, a current ratio of 13.33 and a quick ratio of 13.33. The company has a 50-day simple moving average of $9.94 and a 200-day simple moving average of $8.35.

COMPASS Pathways (NASDAQ:CMPS) last issued its quarterly earnings results on Thursday, February 29th. The company reported ($0.53) EPS for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.16). On average, equities analysts anticipate that COMPASS Pathways will post -2.4 earnings per share for the current year.

Insider Buying and Selling at COMPASS Pathways

In other COMPASS Pathways news, Director George Jay Goldsmith sold 25,750 shares of COMPASS Pathways stock in a transaction that occurred on Monday, January 22nd. The shares were sold at an average price of $8.35, for a total transaction of $215,012.50. Following the transaction, the director now directly owns 4,172,404 shares of the company’s stock, valued at $34,839,573.40. The sale was disclosed in a filing with the SEC, which is available at this link. In other COMPASS Pathways news, Director George Jay Goldsmith sold 25,750 shares of COMPASS Pathways stock in a transaction that occurred on Monday, January 22nd. The shares were sold at an average price of $8.35, for a total transaction of $215,012.50. Following the transaction, the director now directly owns 4,172,404 shares of the company’s stock, valued at $34,839,573.40. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director Ekaterina Malievskaia sold 11,862 shares of the company’s stock in a transaction on Friday, February 23rd. The shares were sold at an average price of $10.06, for a total transaction of $119,331.72. Following the completion of the transaction, the director now owns 4,110,338 shares of the company’s stock, valued at $41,350,000.28. The disclosure for this sale can be found here. Insiders have sold a total of 166,351 shares of company stock valued at $1,553,923 over the last ninety days. Corporate insiders own 23.99% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. ARK Investment Management LLC boosted its stake in shares of COMPASS Pathways by 7.6% in the fourth quarter. ARK Investment Management LLC now owns 2,618,871 shares of the company’s stock valued at $22,915,000 after purchasing an additional 186,040 shares during the period. Vivo Capital LLC purchased a new position in shares of COMPASS Pathways in the third quarter valued at $11,899,000. RA Capital Management L.P. purchased a new position in shares of COMPASS Pathways in the third quarter valued at $9,516,000. Affinity Asset Advisors LLC purchased a new position in shares of COMPASS Pathways in the fourth quarter valued at $4,812,000. Finally, Laurion Capital Management LP boosted its stake in shares of COMPASS Pathways by 169.7% in the third quarter. Laurion Capital Management LP now owns 510,907 shares of the company’s stock valued at $3,781,000 after purchasing an additional 321,500 shares during the period. 46.19% of the stock is currently owned by hedge funds and other institutional investors.

COMPASS Pathways Company Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.